Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease

Molecules. 2022 Nov 14;27(22):7855. doi: 10.3390/molecules27227855.

Abstract

Novel derivatives based on 6-methyluracil and condensed uracil, 2,4-quinazoline-2,4-dione, were synthesized with terminal meta- and para-benzoate moieties in polymethylene chains at the N atoms of the pyrimidine ring. In the synthesized compounds, the polymethylene chains were varied from having tris- to hexamethylene chains and quaternary ammonium groups; varying substituents (ester, salt, acid) at benzene ring were introduced into the chains and benzoate moieties. In vivo biological experiments demonstrated the potency of these compounds in decreasing the number of β-amyloid plaques and their suitability for the treatment of memory impairment in a transgenic model of Alzheimer's disease.

Keywords: 6-methyluracil; Alzheimer’s disease; acetylcholinesterase; inhibitors; peripheral anionic site.

MeSH terms

  • Acetylcholinesterase*
  • Alzheimer Disease* / drug therapy
  • Animals
  • Benzoates
  • Disease Models, Animal
  • Memory Disorders / drug therapy
  • Plaque, Amyloid
  • Uracil / pharmacology
  • Uracil / therapeutic use

Substances

  • Acetylcholinesterase
  • Uracil
  • Benzoates